Eton Pharmaceuticals Inc
NASDAQ:ETON

Watchlist Manager
Eton Pharmaceuticals Inc Logo
Eton Pharmaceuticals Inc
NASDAQ:ETON
Watchlist
Price: 11.97 USD -5.38% Market Closed
Market Cap: 321m USD

During the last 3 months Eton Pharmaceuticals Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 15% over this period (open performance analysis).

The last transaction was made on Oct 23, 2024 by Opaleye Management Inc. (Shareholder) , who bought 79.8k USD worth of ETON shares.

Last Transactions:
Opaleye Management Inc.
Shareholder
$+79.8k
Opaleye Management Inc.
Shareholder
$+101.6k
Opaleye Management Inc.
Shareholder
$+232.5k
Brynjelsen Sean
Chief Executive Officer
$+21k
Opaleye Management Inc.
Shareholder
$-116.7k
Opaleye Management Inc.
Shareholder
$-12k
Opaleye Management Inc.
Shareholder
$-1m
Opaleye Management Inc.
Shareholder
$-718.4k
Opaleye Management Inc.
Shareholder
$-205k
Troutman William Wilson
Executive Chairman
$+22.2k
Brynjelsen Sean
Chief Executive Officer
$+43.2k
Opaleye Management Inc.
Shareholder
$-575.1k
Opaleye Management Inc.
Shareholder
$-815.1k
Brynjelsen Sean
Chief Executive Officer
$+29.8k
Opaleye Management Inc.
Shareholder
$-392.4k
Harrow Health, Inc.
$-10.6m
Opaleye Management Inc.
Shareholder
$+2.7m
Brynjelsen Sean
Chief Executive Officer
$+30.8k
Casamento Charles J
Chairman
$+21.4k
Brynjelsen Sean
Chief Executive Officer
$+10.9k
Troutman William Wilson
Executive Chairman
$+30k
Baum Mark L
Chief Executive Officer
$+60k
Maier Paul V
Director
$+30k
Riedel Norbert G
Chief Operating Officer
$+30k
Casamento Charles J
Chairman
$+30k
View All Transactions

During the last 3 months Eton Pharmaceuticals Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 15% over this period (open performance analysis).

The last transaction was made on Oct 23, 2024 by Opaleye Management Inc. (Shareholder) , who bought 79.8k USD worth of ETON shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
1
79.8k USD
6-9
months
1
334.1k USD
9-12
months
No Insider Transactions
0
0 USD

Eton Pharmaceuticals Inc
Insider Trading Chart

Eton Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Eton Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Eton Pharmaceuticals Inc
Glance View

Market Cap
319.7m USD
Industry
Pharmaceuticals

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.

ETON Intrinsic Value
21.38 USD
Undervaluation 44%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top